Precision Neuroscience
Develops a brain-computer interface intended to help people with paralysis operate digital devices.
$250MSeries D
ParticipantI
Invus
Activity from announced rounds
Activity in this selectionOct 26, 2026 · Healthtech · Jan 1, 2026
Invus is the investment-firm name used by Encoded Therapeutics and in LifeMine transaction-counsel coverage.
Recorded funding activity
Encoded develops precision gene therapies for neurological disorders. LifeMine uses fungal genomes for drug discovery, while City develops RNA-interference medicines. The records identify different therapeutic approaches without substituting an unnamed parent or fund.
- Rounds participated in
- 5
- Confirmed lead rounds
- 0 3 roles undisclosed
- New companies
- 5 First participation on record · 0 follow-on
- Funding in participating rounds
- $705M 4 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
5 in this selectionLifeMine Therapeutics
Develops fungal genome-derived therapeutics for organ transplant rejection
$263MSeries D+Series E
Role not disclosedCity Therapeutics
City Therapeutics develops RNA-interference therapeutics and an engineering platform across disease areas.
$99.5MSeries B
Role not disclosedContraline
Develops hormonal and non-hormonal male contraceptives for men and couples globally
$92.5MSeries B
Role not disclosedCorxel Pharmaceuticals
Corxel Pharmaceuticals develops clinical-stage medicines for cardiometabolic diseases, including obesity, diabetes, stroke and hypertension.
≤$287MSeries D1
Participant